Literature DB >> 8642705

Human immunodeficiency virus type 2 glycoprotein enhancement of particle budding: role of the cytoplasmic domain.

G D Ritter1, G Yamshchikov, S J Cohen, M J Mulligan.   

Abstract

Previous studies have shown that the glycoprotein cytoplasmic domains of human immunodeficiency virus type 2 (HIV-2) or simian immunodeficiency virus of macaques modulate biological activities of the viral glycoprotein complex, including syncytium formation, exterior glycoprotein conformation, and glycoprotein incorporation into budding virus particles. We have now utilized a recombinant expression system to study interactions of full-length or truncated HIV-2 glycoproteins with coexpressed HIV-2 Gag proteins which self-assemble and bud as virus-like particles. Interestingly, budding of HIV-2 virus-like particles from cells was enhanced 5- to 24-fold when Gag was coexpressed with the full-length HIV-2 glycoprotein, compared with Gag expressed either alone or with a truncated HIV-2 glycoprotein. The results obtained in this model system indicate that an additional effect of the lengthy cytoplasmic domain of the glycoprotein of HIV-2 is enhancement of particle budding. We speculate that the cytoplasmic domain of the viral glycoprotein of HIV-2 enhances budding by (i) potentiation of Gag structure or function or (ii) membrane modulation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8642705      PMCID: PMC190121     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  66 in total

1.  Effect of mutations affecting the p6 gag protein on human immunodeficiency virus particle release.

Authors:  H G Göttlinger; T Dorfman; J G Sodroski; W A Haseltine
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-15       Impact factor: 11.205

2.  Human immunodeficiency virus envelope protein determines the site of virus release in polarized epithelial cells.

Authors:  R J Owens; J W Dubay; E Hunter; R W Compans
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-01       Impact factor: 11.205

3.  The complete nucleotide sequence of a pathogenic molecular clone of simian immunodeficiency virus.

Authors:  D A Regier; R C Desrosiers
Journal:  AIDS Res Hum Retroviruses       Date:  1990-11       Impact factor: 2.205

4.  A structural correlation between lentivirus transmembrane proteins and natural cytolytic peptides.

Authors:  M A Miller; R F Garry; J M Jaynes; R C Montelaro
Journal:  AIDS Res Hum Retroviruses       Date:  1991-06       Impact factor: 2.205

5.  The cytoplasmic tail of HIV-1 gp160 contains regions that associate with cellular membranes.

Authors:  O K Haffar; D J Dowbenko; P W Berman
Journal:  Virology       Date:  1991-01       Impact factor: 3.616

6.  Membrane interactions of synthetic peptides corresponding to amphipathic helical segments of the human immunodeficiency virus type-1 envelope glycoprotein.

Authors:  S K Srinivas; R V Srinivas; G M Anantharamaiah; J P Segrest; R W Compans
Journal:  J Biol Chem       Date:  1992-04-05       Impact factor: 5.157

7.  Cytopathic variants of an attenuated isolate of human immunodeficiency virus type 2 exhibit increased affinity for CD4.

Authors:  J A Hoxie; L F Brass; C H Pletcher; B S Haggarty; B H Hahn
Journal:  J Virol       Date:  1991-09       Impact factor: 5.103

8.  Human immunodeficiency virus type 2 envelope glycoprotein: differential CD4 interactions of soluble gp120 versus the assembled envelope complex.

Authors:  M J Mulligan; G D Ritter; M A Chaikin; G V Yamshchikov; P Kumar; B H Hahn; R W Sweet; R W Compans
Journal:  Virology       Date:  1992-03       Impact factor: 3.616

9.  Natural protection against HIV-1 infection provided by HIV-2.

Authors:  K Travers; S Mboup; R Marlink; A Guèye-Nidaye; T Siby; I Thior; I Traore; A Dieng-Sarr; J L Sankalé; C Mullins
Journal:  Science       Date:  1995-06-16       Impact factor: 47.728

10.  A single amino acid change in the cytoplasmic domain of the simian immunodeficiency virus transmembrane molecule increases envelope glycoprotein expression on infected cells.

Authors:  C C LaBranche; M M Sauter; B S Haggarty; P J Vance; J Romano; T K Hart; P J Bugelski; M Marsh; J A Hoxie
Journal:  J Virol       Date:  1995-09       Impact factor: 5.103

View more
  34 in total

Review 1.  Viroporins customize host cells for efficient viral propagation.

Authors:  Kristina M Giorda; Daniel N Hebert
Journal:  DNA Cell Biol       Date:  2013-08-14       Impact factor: 3.311

Review 2.  Novel approaches to inhibiting HIV-1 replication.

Authors:  Catherine S Adamson; Eric O Freed
Journal:  Antiviral Res       Date:  2009-09-24       Impact factor: 5.970

Review 3.  Foamy viruses are unconventional retroviruses.

Authors:  M L Linial
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

4.  Minimal requirement for a lentivirus vector based on human immunodeficiency virus type 1.

Authors:  V N Kim; K Mitrophanous; S M Kingsman; A J Kingsman
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

5.  A sorting motif localizes the foamy virus glycoprotein to the endoplasmic reticulum.

Authors:  P A Goepfert; K L Shaw; G D Ritter; M J Mulligan
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

6.  Conformational changes induced by a single amino acid substitution in the trans-membrane domain of Vpu: implications for HIV-1 susceptibility to channel blocking drugs.

Authors:  Sang Ho Park; Stanley J Opella
Journal:  Protein Sci       Date:  2007-08-31       Impact factor: 6.725

7.  Tetherin-mediated restriction of filovirus budding is antagonized by the Ebola glycoprotein.

Authors:  Rachel L Kaletsky; Joseph R Francica; Caroline Agrawal-Gamse; Paul Bates
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-28       Impact factor: 11.205

8.  Vpu directs the degradation of the human immunodeficiency virus restriction factor BST-2/Tetherin via a {beta}TrCP-dependent mechanism.

Authors:  Janet L Douglas; Kasinath Viswanathan; Matthew N McCarroll; Jean K Gustin; Klaus Früh; Ashlee V Moses
Journal:  J Virol       Date:  2009-06-10       Impact factor: 5.103

9.  Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2.

Authors:  Bin Jia; Ruth Serra-Moreno; William Neidermyer; Andrew Rahmberg; John Mackey; Ismael Ben Fofana; Welkin E Johnson; Susan Westmoreland; David T Evans
Journal:  PLoS Pathog       Date:  2009-05-15       Impact factor: 6.823

10.  Anti-tetherin activities in Vpu-expressing primate lentiviruses.

Authors:  Su Jung Yang; Lisa A Lopez; Heiko Hauser; Colin M Exline; Kevin G Haworth; Paula M Cannon
Journal:  Retrovirology       Date:  2010-02-18       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.